EA200201053A1 - Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства - Google Patents

Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства

Info

Publication number
EA200201053A1
EA200201053A1 EA200201053A EA200201053A EA200201053A1 EA 200201053 A1 EA200201053 A1 EA 200201053A1 EA 200201053 A EA200201053 A EA 200201053A EA 200201053 A EA200201053 A EA 200201053A EA 200201053 A1 EA200201053 A1 EA 200201053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hypertrophy
treatment
bradicardic
application
myocardial diseases
Prior art date
Application number
EA200201053A
Other languages
English (en)
Other versions
EA006977B1 (ru
Inventor
Юрген Дэммген
Брайан Гат
Рандольф Зайдлер
Original Assignee
Бёрингер Ингельхайм Фарма Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Кг filed Critical Бёрингер Ингельхайм Фарма Кг
Publication of EA200201053A1 publication Critical patent/EA200201053A1/ru
Publication of EA006977B1 publication Critical patent/EA006977B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В заявке описано применение по новому назначению брадикардических веществ, таких как блокатор Са-каналов, бета-блокатор или блокатор i-каналов, среди которых блокаторы i-каналов являются предпочтительными, необязательно в сочетании с воздействующим на сердечную деятельность веществом для индуцирования регресса связанных с гипертрофией заболеваний миокарда, прежде всего для лечения идиопатических гипертрофических кардиомиопатий (ГКМ) у человека и домашних животных.Отчет о международном поиске был опубликован 2002.06.20.
EA200201053A 2000-04-13 2001-04-07 Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства EA006977B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (2)

Publication Number Publication Date
EA200201053A1 true EA200201053A1 (ru) 2003-02-27
EA006977B1 EA006977B1 (ru) 2006-06-30

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201053A EA006977B1 (ru) 2000-04-13 2001-04-07 Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства

Country Status (33)

Country Link
US (2) US7208508B2 (ru)
EP (2) EP1666042A3 (ru)
JP (1) JP3905386B2 (ru)
KR (1) KR20020089453A (ru)
CN (1) CN1245963C (ru)
AT (1) ATE330588T1 (ru)
AU (2) AU7048401A (ru)
BG (1) BG65816B1 (ru)
BR (1) BR0109996A (ru)
CA (2) CA2575059A1 (ru)
CY (1) CY1105081T1 (ru)
CZ (1) CZ300549B6 (ru)
DE (2) DE10018401A1 (ru)
DK (1) DK1276476T3 (ru)
EA (1) EA006977B1 (ru)
EE (1) EE05099B1 (ru)
ES (1) ES2266216T3 (ru)
HR (1) HRP20020815A2 (ru)
HU (1) HU228387B1 (ru)
IL (2) IL152103A0 (ru)
ME (1) MEP45908A (ru)
MX (1) MXPA02009935A (ru)
NO (1) NO330311B1 (ru)
NZ (1) NZ521934A (ru)
PL (1) PL215235B1 (ru)
PT (1) PT1276476E (ru)
RS (1) RS51478B (ru)
SI (1) SI1276476T1 (ru)
SK (1) SK286075B6 (ru)
TR (1) TR200202326T2 (ru)
UA (1) UA78679C2 (ru)
WO (1) WO2001078699A2 (ru)
ZA (1) ZA200208162B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
NZ541454A (en) * 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
EP1917979A4 (en) * 2005-08-23 2009-06-03 Astellas Pharma Inc THERAPEUTICS FOR PREVIOUS LIVING ROOMS
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
BR112014003117A2 (pt) * 2011-08-12 2017-06-13 Boehringer Ingelheim Vetmedica Gmbh inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts
JP7050893B2 (ja) 2017-07-07 2022-04-08 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3541811A1 (de) 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
CA2172497A1 (en) * 1993-09-24 1995-03-30 Song Liu Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ES2552639T3 (es) * 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
ATE330588T1 (de) 2006-07-15
CA2404120C (en) 2008-01-22
CA2575059A1 (en) 2001-10-25
NO20024924L (no) 2002-10-11
MXPA02009935A (es) 2003-02-12
TR200202326T2 (tr) 2003-03-21
CN1422153A (zh) 2003-06-04
MEP45908A (en) 2011-02-10
CN1245963C (zh) 2006-03-22
ZA200208162B (en) 2003-10-17
EP1666042A2 (de) 2006-06-07
BG65816B1 (bg) 2010-01-29
NO20024924D0 (no) 2002-10-11
AU7048401A (en) 2001-10-30
US20070155679A1 (en) 2007-07-05
JP3905386B2 (ja) 2007-04-18
AU2001270484B2 (en) 2007-01-25
EE200200590A (et) 2004-04-15
JP2003535050A (ja) 2003-11-25
DE10018401A1 (de) 2001-10-25
EA006977B1 (ru) 2006-06-30
SK14582002A3 (sk) 2003-03-04
CZ300549B6 (cs) 2009-06-10
NZ521934A (en) 2007-05-31
UA78679C2 (en) 2007-04-25
HUP0300917A3 (en) 2009-04-28
CA2404120A1 (en) 2001-10-25
CY1105081T1 (el) 2009-11-04
RS51478B (sr) 2011-04-30
IL152103A0 (en) 2003-07-31
HUP0300917A2 (hu) 2003-08-28
EE05099B1 (et) 2008-12-15
CZ20023752A3 (cs) 2003-03-12
US20040014795A1 (en) 2004-01-22
DE50110262D1 (de) 2006-08-03
US7208508B2 (en) 2007-04-24
PL215235B1 (pl) 2013-11-29
WO2001078699A3 (de) 2002-06-20
SI1276476T1 (sl) 2006-10-31
KR20020089453A (ko) 2002-11-29
EP1276476B1 (de) 2006-06-21
BR0109996A (pt) 2003-05-27
EP1276476A2 (de) 2003-01-22
IL152103A (en) 2008-07-08
YU76902A (sh) 2006-05-25
PT1276476E (pt) 2006-09-29
ES2266216T3 (es) 2007-03-01
BG107103A (bg) 2003-04-30
PL357827A1 (en) 2004-07-26
HU228387B1 (en) 2013-03-28
SK286075B6 (sk) 2008-03-05
WO2001078699A2 (de) 2001-10-25
DK1276476T3 (da) 2006-08-14
NO330311B1 (no) 2011-03-28
EP1666042A3 (de) 2006-06-21
HRP20020815A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
EA200201053A1 (ru) Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
DE50012238D1 (de) Desinfizierendes waschen empfindlicher textilien mit persäuren
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
MA25890A1 (fr) Composition de traitement de tissu avec auxiliaire de rincage, ensemble la contenant et procede pour son utilisation
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EE200100647A (et) Ühendite uus kasutamine antibakteriaalsete ainetena
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
NO942817L (no) Tricykliske benzazepiner som rasopressin-antagonister
EA199900693A1 (ru) Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
EA200001039A1 (ru) Кальцилитические соединения
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
BR0200626A (pt) Agonistas beta3 e seus usos
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
TR200102944T2 (tr) İntegrin reseptör ligandları
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
PA8436501A1 (es) Ligandos espirociclicos de un subtipo de receptor de la dopamina.

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU